Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study

Open access

Abstract

INTRODUCTION: This study aimed to assess the safety and effectiveness of semaglutide, administered either by weekly subcutaneous (SC) injection or orally, in real-life practice in Saudi Arabia in individuals with type 2 diabetes mellitus (T2DM). METHODS: A retrospective chart review study was conducted at 18 Saudi Arabia centers. An accredited centralized institutional review board approved the study. Medical records were included for individuals of any age ≥ 18 years with uncontrolled T2DM. The primary outcome measure was the laboratory glycated hemoglobin (HbA1c) level. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after 6 and 12 months of semaglutide initiation. RESULTS: The analysis of this study included 1223 patients with uncontrolled T2DM (HbA1c > 7%). The mean (SD) baseline HbA1c was 10.02% (1.17). HbA1c was reduced by an average of 3.02% (0.84) and 3.17% (0.84) at 6 and 12 months, respectively. Results of a repeated measure analysis of variance (ANOVA) indicated significant differences in HbA1c (p value < 0.001). HbA1c levels at 6 and 12 months were significantly lower, 7.00% (0.70) and 6.85% (0.69), than at baseline, 10.02% (1.17). About 193 patients (56.4%) of the 295 patients having HbA1c < 9% achieved HbA1c of 5.7% or less. The frequency of hypoglycemia events was 4.60 (1.10) in the 3 months before semaglutide was initiated. The frequency of hypoglycemia events in the last 3 months was 2.30 (0.80) events and 0.80 (0.50) events at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.07% (1.53) and 19.89% (4.07) at 6 and 12 months, respectively. Lipid profile and blood pressure were improved at 6 and 12 months. CONCLUSION: Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01516-z

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 HbA1c reduction
Fig. 1 HbA1c reductionCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 4

  1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 8th edition, 2017, http://www.diabetesatlas.org.
  2. IDF Diabetes Atlas 2021-10th edition. Saudi Arabia: Diabetes report 2010–2045. https://www.diabetesatlas.org/data/en/country/174/sa.html. Accessed 8 Mar 2023.
  3. IDF Diabetes Atlas 2021–10th edition. Middle East and North Africa fact sheet 2019. https://diabetesatlas.org/upload/resources/material/20191218_144557_mena_factsheet_en.pdf. Accessed 8 Mar 2023.
  4. Napoli R, Avogaro A, Formoso G, et al. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian Diabetes Society. Nutr Metab Cardiovasc Dis. 2021;21:S0939–4753(21)00410–5.

Cited by

Metadata

Authors
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., Aljuhani, N., Aldabeis, A., Alamri, M., Maghawry, W., Alzaman, N., Alshaikh, A., M. Alnozha, O., Issak, E. R., & Alsifri, S.
Affiliations
  • King Abdul Aziz University Hospital (SA)
  • King Fahd Medical City (SA)
  • King Saud Medical City (SA)
  • National Guard Health Affairs (SA)
  • Security Forces Hospital (SA)
  • East Jeddah Hospital (SA)
  • Armed Forces Hospital Southern Region (SA)
  • Taibah University (SA)
  • Ain Shams University (EG)
  • Armed Forces Hospital (SA)
Corresponding author
Issak, Emad R.
Venue
Diabetes Therapy
Published
2023-12-19
Volume
15
Issue
2
Pages
473-485
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4389916331
Cited by
16
References
33
Citations by year
2026: 4 · 2025: 8 · 2024: 4
FWCI
3.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, HbA1c, HbA1c reduction, hypoglycemia, weight loss, body mass index, oral semaglutide, real-world effectiveness, drug safety, Saudi Arabia, uncontrolled diabetes, fasting blood glucose, GLP-1 receptor agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study. https://app.cochat.ai/papers/10.1007/s13300-023-01516-z
The paper
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., Aljuhani, N., Aldabeis, A., Alamri, M., Maghawry, W., Alzaman, N., Alshaikh, A., M. Alnozha, O., Issak, E. R., & Alsifri, S. (2024). Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01516-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.